ライフサイエンスコーパス: age-related macular degeneration

1 (PRN) in patients with subfoveal neovascular age-related macular degeneration).

2 d improved visual outcomes for patients with age-related macular degeneration.

3 s with common eye diseases like glaucoma and age-related macular degeneration.

4 the protective effect of FHR-1 deficiency in age-related macular degeneration.

5 particularly in eyes with advanced stages of age-related macular degeneration.

6 atory role of Toll-like receptor 2 (TLR2) in age-related macular degeneration.

7 an retinal degenerative disorders, including age-related macular degeneration.

8 of TGF-beta signaling in the pathogenesis of age-related macular degeneration.

9 uremic syndrome and C3 glomerulopathies, and age-related macular degeneration.

10 oking may have relevance for the etiology of age-related macular degeneration.

11 ral vision in many patients with neovascular age-related macular degeneration.

12 e of vision loss in diabetic retinopathy and age-related macular degeneration.

13 uding retinitis pigmentosa (RP) and atrophic age-related macular degeneration.

14 central vision and shows symptoms similar to age-related macular degeneration.

15 ks of proliferative diabetic retinopathy and age-related macular degeneration.

16 proliferative diabetic retinopathy, and wet age-related macular degeneration.

17 uncorrected refractive error, cataracts, and age-related macular degeneration.

18 to their recently reported association with age-related macular degeneration.

19 inal disorders such as Stargardt disease and age-related macular degeneration.

20 dense deposit disease and the ocular disease age-related macular degeneration.

21 bretinal fibrosis development in neovascular age-related macular degeneration.

22 idualized treatment regimens for neovascular age-related macular degeneration.

23 edical need in the management of neovascular age-related macular degeneration.

24 PE and Bruch's membrane alterations, such as age-related macular degeneration.

25 can resolve ambiguity about cone survival in age-related macular degeneration.

26 ory diseases, including Behcet's disease and age-related macular degeneration.

27 a novel therapeutic approach for neovascular age-related macular degeneration.

28 potential long-term treatment option for wet age-related macular degeneration.

29 e similar to those observed in patients with age-related macular degeneration.

30 ntly outweigh the benefits for patients with age-related macular degeneration.

31 (CNV) surgically removed from patients with age-related macular degeneration.

32 sFLT01 in patients with advanced neovascular age-related macular degeneration.

33 g proliferative diabetic retinopathy and wet age-related macular degeneration.

34 ch as retinitis pigmentosa (RP) and atrophic age-related macular degeneration.

35 rders as proliferative vitreoretinopathy and age-related macular degeneration.

36 PE) is a key site of injury in inherited and age-related macular degenerations.

37 ong women, with no sex difference related to age-related macular degeneration (0.91 [0.70-1.14]).

38 ractive error (61.3%), cataract (13.2%), and age-related macular degeneration (10.3%).

39 gies were observed in 55.6 % of photographs (age-related macular degeneration: 34.2 %; diabetic retin

40 Age-related macular degeneration 4 included neovascular

41 Thirty-five participants with neovascular age-related macular degeneration, 7 of whom were treatme

42 .6 million [18.2 million to 109.6 million]), age-related macular degeneration (8.4 million [0.9 milli

43 Age-related macular degeneration according to fundus pho

44 ruited, with either persistent amblyopia and age-related macular degeneration (AMB + AMD), or with bi

45 ega-3 PUFA supplementation on progression of age related macular degeneration (AMD).

46 Age-related macular degeneration (AMD) affects millions

47 Age-related macular degeneration (AMD) affects the retin

48 Although numerous common age-related macular degeneration (AMD) alleles have been

49 bevacizumab for the treatment of neovascular age-related macular degeneration (AMD) among Medicare be

50 23 (60%) had geographic atrophy secondary to age-related macular degeneration (AMD) and 2 eyes (5%) h

51 ix of 15 eyes were diagnosed with coincident age-related macular degeneration (AMD) and 2 with myopic

52 nsecutive patients with AVLs associated with age-related macular degeneration (AMD) and adult-onset f

53 c syndrome (aHUS), also confers high risk of age-related macular degeneration (AMD) and associates wi

54 y of systematic reviews of interventions for age-related macular degeneration (AMD) and described the

55 To study associations between early and late age-related macular degeneration (AMD) and neovascular A

56 Age-related macular degeneration (AMD) and proliferative

57 Age-related macular degeneration (AMD) and related macul

58 hy (OCT) images of patients with neovascular age-related macular degeneration (AMD) and to demonstrat

59 o late-stage non-neovascular and neovascular age-related macular degeneration (AMD) and to provide re

60 roidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) and VA between 20

61 ence of ethnicity on the association between age-related macular degeneration (AMD) and vision-specif

62 gh currently available treatment options for age-related macular degeneration (AMD) are limited, part

63 a reported decline in the risk of developing age-related macular degeneration (AMD) continued for peo

64 Age-related macular degeneration (AMD) has been associat

65 ctor H (CFH) gene and their association with age-related macular degeneration (AMD) have been describ

66 the following cardinal features of human dry age-related macular degeneration (AMD) in 12-month-old m

67 s; retinal tear in 8.9% of eyes; neovascular age-related macular degeneration (AMD) in 7.9% of eyes;

68 rmine the 6-year incidence of early and late age-related macular degeneration (AMD) in a Singaporean

69 secutive naive eyes diagnosed with exudative age-related macular degeneration (AMD) in comparison wit

70 ce to a Mediterranean diet and prevalence of age-related macular degeneration (AMD) in countries rang

71 h pathogenesis of both Stargardt disease and age-related macular degeneration (AMD) in humans, deleti

72 l abnormalities to disease in general and in age-related macular degeneration (AMD) in particular is

73 evaluate the incidence of intermediate-stage age-related macular degeneration (AMD) in patients with

74 sion, pseudodrusen, and the presence of late age-related macular degeneration (AMD) in the fellow eye

75 tween such consumption and the prevalence of age-related macular degeneration (AMD) in the United Sta

76 The genetic architecture of age-related macular degeneration (AMD) involves numerous

77 Age-related macular degeneration (AMD) is a frequent, co

78 Age-related macular degeneration (AMD) is a leading caus

79 Age-related macular degeneration (AMD) is a leading caus

80 Age-related macular degeneration (AMD) is a leading caus

81 Age-related macular degeneration (AMD) is a major cause

82 Age-related macular degeneration (AMD) is a major cause

83 Age-related macular degeneration (AMD) is a major cause

84 Age-related macular degeneration (AMD) is a major cause

85 Importance: Age-related macular degeneration (AMD) is a multifactori

86 Age-related macular degeneration (AMD) is a progressive

87 Age-related macular degeneration (AMD) is a progressive

88 Photoreceptor degeneration in age-related macular degeneration (AMD) is associated wit

89 Neovascular age-related macular degeneration (AMD) is characterized

90 Age-related macular degeneration (AMD) is the leading ca

91 Advanced age-related macular degeneration (AMD) is the leading ca

92 Age-related macular degeneration (AMD) is the leading ca

93 Age-related macular degeneration (AMD) is the leading ca

94 Age-related macular degeneration (AMD) is the leading ca

95 Age-related macular degeneration (AMD) is the most commo

96 plant-derived omega-3 (n-3) fatty acid, and age-related macular degeneration (AMD) is unclear.

97 The incidence of age-related macular degeneration (AMD) is unknown in Afr

98 ce: Population-based prevalence estimates of age-related macular degeneration (AMD) need to be determ

99 To evaluate the impact of age-related macular degeneration (AMD) on short out-loud

100 with BVI, caused by persistent amblyopia and age-related macular degeneration (AMD) or by bilateral A

101 at-and-extend (TREX) regimen for neovascular age-related macular degeneration (AMD) or fellow control

102 Three controls without age-related macular degeneration (AMD) or retinal diseas

103 were co-evaluated for protection against wet age-related macular degeneration (AMD) over a 6month per

104 -old control, 1 from a 78-year-old exudative age-related macular degeneration (AMD) patient, 1 from a

105 type 1 neovascularization (NV) in eyes with age-related macular degeneration (AMD) receiving anti-va

106 RNAs (miRs) in diabetic retinopathy (DR) and age-related macular degeneration (AMD) remains unclear.

107 cted loss-of-function (pLoF) variants within age-related macular degeneration (AMD) risk loci and AMD

108 homocysteine (tHcy) and B vitamin levels and age-related macular degeneration (AMD) risk.

109 en genetic predictors of lipid fractions and age-related macular degeneration (AMD) risk.

110 stionnaire (LLQ) in patients with a range of age-related macular degeneration (AMD) severity are asso

111 There is a subset of eyes with neovascular age-related macular degeneration (AMD) that have persist

112 ographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) that leads to pro

113 aphic atrophy (GA) secondary to nonexudative age-related macular degeneration (AMD) through multimoda

114 visual outcome in patients with neovascular age-related macular degeneration (AMD) treated initially

115 ve models of anatomic outcome in neovascular age-related macular degeneration (AMD) treated with as-n

116 Patients with intermediate age-related macular degeneration (AMD) using a home moni

117 clinical trial evaluating progression of dry age-related macular degeneration (AMD) using color photo

118 plasma metabolomic profile of patients with age-related macular degeneration (AMD) using mass spectr

119 To study choriocapillaris blood flow in age-related macular degeneration (AMD) using optical coh

120 he retinal pigment epithelium (RPE) cells in age-related macular degeneration (AMD) using polarimetry

121 Most classification systems for age-related macular degeneration (AMD) were developed fr

122 d be part of standard care for patients with age-related macular degeneration (AMD) who are being con

123 Patients aged >/=50 years with subfoveal wet age-related macular degeneration (AMD) who had best-corr

124 linical trials for the study of nonexudative age-related macular degeneration (AMD) with an emphasis

125 y 2 Ancillary SD OCT study participants with age-related macular degeneration (AMD) with bilateral la

126 DS2) participants with at least intermediate age-related macular degeneration (AMD) with control subj

127 % aflibercept; 62.7% were performed to treat age-related macular degeneration (AMD), 16.1% to treat d

128 RD shows striking phenotypic similarities to age-related macular degeneration (AMD), a common and gen

129 d the choriocapillaris are characteristic of age-related macular degeneration (AMD), a common vision-

130 ltering variants known to be associated with age-related macular degeneration (AMD), a frequent macul

131 Age-related macular degeneration (AMD), a leading cause

132 Age-related macular degeneration (AMD), a leading contri

133 factor H (CFH), show strong association with age-related macular degeneration (AMD), a major cause of

134 Age-related macular degeneration (AMD), a multifactorial

135 e an important factor in the pathogenesis of age-related macular degeneration (AMD), although direct

136 s in humans have implicated AP activation in age-related macular degeneration (AMD), and AP dysfuncti

137 ortality with visual acuity (VA) impairment, age-related macular degeneration (AMD), and cataract sur

138 g evidence of the importance of nutrition in age-related macular degeneration (AMD), but few studies

139 neovascularization (CNV) among patients with age-related macular degeneration (AMD), but no economic

140 To test potential treatments for age-related macular degeneration (AMD), clinical trials

141 oidal vasculopathy (PCV), a subtype of 'wet' age-related macular degeneration (AMD), constitutes up t

142 Other diseases, such as age-related macular degeneration (AMD), develop late in

143 kemia, Alzheimer's disease, hemochromatosis, age-related macular degeneration (AMD), diabetes mellitu

144 linical trials for management of neovascular age-related macular degeneration (AMD), diabetic macular

145 cross a diverse range of diseases, including age-related macular degeneration (AMD), glaucoma and ref

146 ar diseases, including diabetic retinopathy, age-related macular degeneration (AMD), glaucoma, catara

147 Patients with age-related macular degeneration (AMD), myopia, pachycho

148 In age-related macular degeneration (AMD), rare variants in

149 ative diseases including dry and neovascular age-related macular degeneration (AMD), retinitis pigmen

150 Neovascular pathologies in the eye like age-related macular degeneration (AMD), the diabetic ret

151 ial diagnostic and therapeutic biomarker for age-related macular degeneration (AMD), we sequenced the

152 atous proliferation, a subset of neovascular age-related macular degeneration (AMD), which is associa

153 ctively recruited patients with intermediate age-related macular degeneration (AMD), without other vi

154 es (ODS) and examine their associations with age-related macular degeneration (AMD)-related features

155 a white population, of physical activity and age-related macular degeneration (AMD)-the main cause of

156 and the intermediate and advanced stages of age-related macular degeneration (AMD).

157 izumab with aflibercept to treat neovascular age-related macular degeneration (AMD).

158 al OCT images from images from patients with Age-related Macular Degeneration (AMD).

159 light contribute to the oxidative stress in Age-related macular degeneration (AMD).

160 ement factor H (CFH) confer greater risk for age-related macular degeneration (AMD).

161 d thereby protect against the development of age-related macular degeneration (AMD).

162 lateral geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

163 rders, such as diabetic retinopathy (DR) and age-related macular degeneration (AMD).

164 ays an essential role in the pathogenesis of age-related macular degeneration (AMD).

165 ance [IR] imaging) in eyes with nonexudative age-related macular degeneration (AMD).

166 ion of choroidal neovascularization (CNV) in age-related macular degeneration (AMD).

167 s a known precursor to geographic atrophy in age-related macular degeneration (AMD).

168 reduction of the risk of vision loss due to Age-Related Macular Degeneration (AMD).

169 ophy based on OCT findings in the setting of age-related macular degeneration (AMD).

170 n autophagy contribute to the progression of age-related macular degeneration (AMD).

171 are pivotal to the pathogenic progression of age-related macular degeneration (AMD).

172 degenerative conditions like RP and atrophic age-related macular degeneration (AMD).

173 licated in the pathogenesis of inherited and age-related macular degeneration (AMD).

174 hway, are altered in patients with exudative age-related macular degeneration (AMD).

175 s entered clinical trials as a treatment for age-related macular degeneration (AMD).

176 on homeostasis may be a pathogenic factor in age-related macular degeneration (AMD).

177 or (VEGF) drug, in patients with neovascular age-related macular degeneration (AMD).

178 e and inflammatory retinal disorders such as age-related macular degeneration (AMD).

179 provide insights into disease states such as age-related macular degeneration (AMD).

180 -box" approaches, for automated diagnosis of Age-related Macular Degeneration (AMD).

181 owth factor (VEGF) treatment for neovascular age-related macular degeneration (AMD).

182 systemic inflammation increases the risk of age-related macular degeneration (AMD).

183 ceptor alterations in eyes with intermediate age-related macular degeneration (AMD).

184 ed high-fat intakes with a high incidence of age-related macular degeneration (AMD).

185 lop drusenoid lesions which are hallmarks of age-related macular degeneration (AMD).

186 s supposed to contribute the pathogenesis of age-related macular degeneration (AMD).

187 ing inflammatory marker associated with late age-related macular degeneration (AMD).

188 LIPC, CFB, and C2 genes are associated with age-related macular degeneration (AMD); however, the ass

189 have been found to be highly associated with age-related macular degeneration (AMD); however, the eff

190 200 OCT volumes of patients with neovascular age-related macular degeneration (AMD, n = 400), diabeti

191 eviews of the 4 most prevalent eye diseases (age-related macular degeneration [AMD], cataract, diabet

192 ms regulating the normal and diseased state (age related macular degeneration, AMD) in the retina.

193 Inherited and age-related macular degenerations (AMDs) are important c

194 uncorrected refractive error, cataracts, and age-related macular degeneration among adults 65 years o

195 ents aged 50 years or older with neovascular age-related macular degeneration and a baseline best-cor

196 To identify GA in age-related macular degeneration and assess treatment, c

197 To report patients with age-related macular degeneration and atypical central re

198 other retinal degenerative diseases such as age-related macular degeneration and diabetic retinopath

199 riant confers the strongest genetic risk for age-related macular degeneration and earlier age at onse

200 tial therapies for retinal diseases, such as age-related macular degeneration and inherited retinal d

201 se vision loss in many eye diseases, such as age-related macular degeneration and macular telangiecta

202 ed with diverse clinical disorders including age-related macular degeneration and paroxysmal nocturna

203 that recombinant I62-CFH (protective against age-related macular degeneration) and V62-CFH functioned

204 ic macular edema, 32 (25.8%) had neovascular age-related macular degeneration, and 32 (25.8%) had oth

205 ye pathologies such as diabetic retinopathy, age-related macular degeneration, and central retinal ve

206 act, uncorrected refractive error, glaucoma, age-related macular degeneration, and diabetic retinopat

207 opathy of prematurity, diabetic retinopathy, age-related macular degeneration, and glaucoma, as well

208 riteria included aphakia, pseudophakia, late age-related macular degeneration, and vision impairment

209 ) treatment regimen with ranibizumab for wet age-related macular degeneration (ARMD) in real life cli

210 d in the retinal pigment epithelium (RPE) of age-related macular degeneration (ARMD) patients and the

211 is associated with neovascularization in wet age-related macular degeneration (ARMD), choriocapillari

212 sregulated in various pathologies, including age-related macular degeneration, arthritis, and cancer.

213 hy of prematurity, diabetic retinopathy, and age-related macular degeneration, as well as corneal dis

214 Age-related macular degeneration automated detection was

215 degeneration (AMB + AMD), or with bilateral age-related macular degeneration (BAMD).

216 itreous bevacizumab injections for exudative age-related macular degeneration between January 1, 2009

217 treatment of ophthalmic diseases, including age-related macular degeneration, cataracts, diabetic re

218 Geographic atrophy is a blinding form of age-related macular degeneration characterized by retina

219 inal fibrosis is an end stage of neovascular age-related macular degeneration, characterized by fibro

220 In age-related macular degeneration, choroidal neovasculari

221 e anterior (dry eye syndrome) and posterior (age-related macular degeneration, diabetic retinopathy a

222 emarks to 3 common, but serious, conditions: age-related macular degeneration (Dr. Fine), diabetic re

223 Patients with treated CNV secondary to age-related macular degeneration from a community-based

224 of European ancestry from the International Age-related Macular Degeneration Genomics Consortium.

225 Ophthalmic diseases, such as age-related macular degeneration, glaucoma, and diabetic

226 than did patients with diabetic retinopathy, age-related macular degeneration, glaucoma, cataract, an

227 vision impairment) and a high prevalence of age-related macular degeneration (>14% of blindness) as

228 Ocular diseases associated with NAION were age-related macular degeneration (HR = 1.29; 95% CI: 1.0

229 phic atrophy (nGA) in eyes with intermediate age-related macular degeneration (iAMD).

230 lationship between plasma HDL-C and risk for age-related macular degeneration; (iii) only some mechan

231 alphaB-crystallin plays multiple roles in age-related macular degeneration, including cytoprotecti

232 ting systematic reviews of interventions for age-related macular degeneration incorporated into clini

233 Age related macular degeneration is the leading cause of

234 Age-related macular degeneration is a leading cause of i

235 Neovascular age-related macular degeneration is among the most commo

236 The other, age-related macular degeneration, is the most common for

237 hat critically contributes to vision loss in age-related macular degeneration, is unclear.

238 al diseases such as retinitis pigmentosa and age related macular degeneration leading to loss of visi

239 tter characterization of genetic profiles in age-related macular degeneration may be important for sc

240 Age-related macular degeneration may be more than a "mac

241 arma AG, Basel, Switzerland) for neovascular age-related macular degeneration (nAMD) after 2 years wh

242 forms of VEGF-A in patients with neovascular age-related macular degeneration (nAMD) demonstrated dra

243 visual outcomes in patients with neovascular age-related macular degeneration (nAMD) during anti-vasc

244 ate preferences of patients with neovascular age-related macular degeneration (nAMD) for different an

245 onthly regimens in patients with neovascular age-related macular degeneration (nAMD) from the TReat a

246 ith intravitreal aflibercept for neovascular age-related macular degeneration (nAMD) in routine clini

247 Describing the natural course of neovascular age-related macular degeneration (nAMD) is essential in

248 Treatment-naive eyes with neovascular age-related macular degeneration (nAMD) tracked by the F

249 ual acuity (VA) in patients with neovascular age-related macular degeneration (nAMD) treated with a s

250 raphic atrophy (GA) in eyes with neovascular age-related macular degeneration (nAMD) treated with ran

251 vents (SAEs) among patients with neovascular age-related macular degeneration (nAMD) who participated

252 over 12 months in patients with neovascular age-related macular degeneration (nAMD) with insufficien

253 jections in patients treated for neovascular age-related macular degeneration (nAMD), diabetic macula

254 nts treated with ranibizumab for neovascular age-related macular degeneration (nAMD), diabetic macula

255 EGF therapy for the treatment of neovascular age-related macular degeneration (nAMD), ophthalmologist

256 mab monotherapy in patients with neovascular age-related macular degeneration (nAMD).

257 el with choroidal neovascularisation akin to age-related macular degeneration, NCD loss attenuated ve

258 etinal vein occlusion (RVO), and neovascular-age related macular degeneration (nvAMD).

259 Neovascular age-related macular degeneration (NVAMD) is the most com

260 phy (OCT) in guiding therapy for neovascular age-related macular degeneration (nvAMD) to the research

261 l other eyes among patients with neovascular age-related macular degeneration (NVAMD) treated with an

262 the prognosis for patients with neovascular age-related macular degeneration (nvAMD).

263 eat-and-extend (TAE) regimen for neovascular age-related macular degeneration (NVAMD).

264 When a patient with neovascular age-related macular degeneration or diabetic macular ede

265 h factor agents for treatment of neovascular age-related macular degeneration or diabetic macular ede

266 jection for chronic retinal diseases such as age-related macular degeneration or diabetic macular ede

267 mab, or 2.0-mg injections of aflibercept for age-related macular degeneration or diabetic macular ede

268 Importance: When a patient with neovascular age-related macular degeneration or diabetic macular ede

269 h factor agents for treatment of neovascular age-related macular degeneration or diabetic macular ede

270 e error, visual field, diabetic retinopathy, age-related macular degeneration, or elevated cup-to-dis

271 High myopia, age-related macular degeneration, or prostaglandin analo

272 aps significantly with sets found by GWAS of age-related macular degeneration (P=1.4 x 10(-12)), ulce

273 se of Alzheimer's disease (P=4.4 x 10(-15)), age-related macular degeneration (P=6.4 x 10(-6)), and P

274 (2017) show that iPSC-derived RPE cells from age-related macular degeneration patients express increa

275 An exemplary search for patients with age-related macular degeneration, performed cataract sur

276 In contrast to neovascular age related macular degeneration, polypoidal choroidal v

277 choroidal neovascularization and neovascular age related macular degeneration presenting with hemorrh

278 reatable eye diseases, of which the main are age-related macular degeneration, retinal vein occlusion

279 folding predictions for proteins involved in age-related macular degeneration, retinitis pigmentosa,

280 ent of degenerative retinal diseases such as age-related macular degeneration, Stargardt disease, and

281 hy of prematurity, diabetic retinopathy, and age-related macular degeneration, threaten the visual he

282 million (17.9 million to 124.1 million), by age-related macular degeneration to 8.8 million (0.8 mil

283 to managing diseases, including stroke, AD, age-related macular degeneration, traumatic brain injury

284 a major cause of blindness for patients with age-related macular degeneration, treat symptoms but not

285 lticenter clinical trials, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT

286 w-up among participants in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT

287 1185 patients enrolled in the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT

288 lticenter clinical trials, the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT

289 ective cohort study within the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT

290 erative diabetic retinopathy and neovascular age-related macular degeneration, uncontrolled angiogene

291 growth factor inhibitors (anti-VEGF) for wet age-related macular degeneration (wAMD), and to acquire

292 with better final vision (P = .007), whereas age-related macular degeneration was associated with poo

293 Age-related macular degeneration was attributed as the m

294 19 patients with advanced neovascular age-related macular degeneration were enrolled in the st

295 A total of 1097 patients with neovascular age-related macular degeneration were randomized to intr

296 V.sFlt-1 subretinal injection in neovascular age-related macular degeneration (wet AMD) over 36 month

297 subretinal drusenoid deposits, a hallmark of age-related macular degeneration, which is a common blin

298 We applied our method to an in-depth GWAS of age-related macular degeneration with 33,976 individuals

299 was supplemented by patients with bilateral age-related macular degeneration with similar decrease o

300 An oral treatment for neovascular age-related macular degeneration would be less burdensom